NAT, including chemotherapy, anti-HER2 therapy and hormonal therapy administered before surgery, has become part of the standard-of-care treatment of patients not only with locally advanced breast cancer but also with operable tumors, particularly in HER2-positive carcinomas and TNBC. The gene discussed is ERBB2; the disease is breast cancer.